Abstract
[Display omitted]
To identify any differences in the characteristics and outcomes of patients with Isolated cardiac sarcoidosis (iCS) vs systemic cardiac sarcoidosis (sCS).
All inpatient encounters in the Nationwide Readmission Database from 2016 to 2021 were analyzed for the rates, predictors, costs and mortality during index and unplanned 90-days readmissions for iCS and sCS patients. Patients with ischemic heart disease were excluded.
1,667 patients were identified (57.8 % male), of which, 1,013 (60.8 %) had iCS and 654 (39.2 %) had sCS. The median (IQR) age of iCS patients was slightly older [57.0 (49.0–66.0) vs 56.0 (48.0–64.0), p = 0.04]. On index admission, iCS patients had higher prevalence of ventricular tachycardia (36.9 % vs 28.8 %, p = 0.001) and catheter ablation (5.6 % vs 2.8 %, p = 0.006). The predictors for all-cause readmissions were Charlson Comorbidity Index (CCI) (HR 1.19, 95 % CI 1.01–1.40, p = 0.04), age (HR 0.98 (0.97–1.00), p = 0.01) and the use of anticoagulant therapy (HR 1.92, 95 % CI 1.35–2.72, p < 0.001). Patients with sCS were more likely to be readmitted with heart failure compared to iCS patients (SHR 3.78, 95 % CI 1.11–12.94, p = 0.03). During subsequent readmission, iCS and sCS patients had comparable rates of in-hospital mortality, median length of stay and healthcare-associated costs. No independent predictors of in-hospital mortality at readmission were ascertained.
Isolated CS patients, when compared to systemic CS, had a greater prevalence of ventricular tachycardia and catheter ablation. They were less likely to be re-hospitalized with heart failure within 90-days. Age, higher CCI, and use of anticoagulant therapy were predictors for all-cause readmissions.